# Selank Research: Mechanism, Studies, and the Honest Gaps > Selank research in depth: how the peptide modulates GABA, enkephalinases, BDNF, and immune signaling — the key studies, cited, plus where the evidence is thin. GABA modulation, enkephalinase inhibition, BDNF, and immune signaling — the study record laid out and cited, with the single-region caveat kept in view. ## The short version Here is **Selank** research without the jargon wall. Selank is a seven-amino-acid peptide that calms anxiety in animals and small human studies — and the interesting part is *how*. It doesn't sedate. Instead it works through several of the brain's own calming systems at once. It makes the brain's main "calm" receptor (GABA) easier to activate [1]. It protects the body's natural feel-good signals (enkephalins) from being broken down [2]. It bumps up a brain-growth protein called BDNF [3], and it even tunes the immune system, because it's a copy of a natural immune peptide [5]. The honest gap, stated up front: nearly all of this comes from Russian research groups, much of it in rodents, with limited replication elsewhere. The findings are interesting and consistent — they are not the same as a globally proven drug. ## Selank acts on GABA — but not like a benzodiazepine Selank's anxiolytic effect centers on the GABA system, the brain's primary "slow down and calm" network. A 2018 review concluded that Selank works as a *positive allosteric modulator* of GABA-receptor binding — it binds a site separate from GABA itself and makes the receptor respond more strongly — with subtype-selective, concentration-dependent activity that differs from benzodiazepines [1]. Notably, Selank could block the modulatory activity of diazepam and olanzapine, suggesting distinct but overlapping binding sites [1]. The gene-level evidence backs this up. A single 300 µg/kg dose in rats changed the expression of 45 genes in the frontal cortex at one hour and 22 genes at three hours — and those shifts correlated positively with the changes GABA itself produces [4]. In other words, Selank pushes the GABA system in its own natural direction rather than overriding it. ## Enkephalinase inhibition: protecting the body's own calm The second mechanism is about the body's natural opioid-like peptides. *Enkephalins* are short calming, pain-modulating molecules the body makes; *enkephalinases* are the enzymes that break them down. In human plasma in the lab, Selank dose-dependently inhibited those enzymes, with a half-maximal inhibitory concentration (IC50) around 15 µM [2]. Why this matters: people with generalized anxiety tend to have a shortened enkephalin half-life. By slowing the breakdown, Selank is proposed to let those endogenous calming signals last longer — a plausible, non-sedating route to anxiety relief that has nothing to do with the GABA pathway [2]. ## BDNF and the hippocampus: a neuroplasticity link Selank also reaches into neuroplasticity — the brain's ability to grow and rewire. Intranasal Selank regulated (increased) **BDNF** (brain-derived neurotrophic factor, a protein that helps neurons survive and adapt) in the rat hippocampus, the brain's memory hub [3]. This links the peptide's nootropic, learning-supportive reputation to a concrete molecular signal. Broader transcriptome work fills in the picture: treatment with Selank altered the hippocampal transcriptome in rats [14], consistent with the gene-expression shifts seen in the cortex and the peptide's wide-ranging CNS effects. ## Selank peptide and the immune system Because Selank is built from tuftsin — an immune-signaling peptide — it carries immunomodulatory activity that classical anxiolytics don't. In patients with anxiety-asthenic disorders, Selank altered the Th1/Th2 cytokine balance and modulated IL-6 expression, leading the authors to call it a novel immunomodulator alongside its anxiolytic action [5]. The pattern repeats under stress: Selank influenced cytokine levels in stressed rats [19], and as an immunomodulator it even showed antiviral activity in experimental influenza infection in mice [20]. It also shifted serotonin and dopamine metabolite levels in mouse brain in a strain-dependent way [18], rounding out a mechanism that spans neurotransmitters, neurotrophins, and immune signaling. ## What the human studies found The human record is small but consistent. A Russian clinical study in generalized anxiety disorder and neurasthenia reported that intranasal Selank produced anxiolytic and mild activating effects comparable to a benzodiazepine comparator — without sedation, cognitive impairment, or withdrawal [6]. A separate clinical study on optimizing anxiety-disorder treatment reported anxiolytic benefit and proposed Selank as an option to refine therapy [16]. In rodents, the anti-anxiety effect is reproducible: heptapeptide Selank reduced both genetically-based and situation-provoked anxiety across two rat strains [13], and in an unpredictable chronic mild stress model, diazepam combined with Selank was the most effective intervention, restoring behavior toward pre-stress levels [7]. ## N-Acetyl Selank **N-Acetyl Selank** is a chemically modified version of Selank carrying an acetyl group on the N-terminus, marketed in research-chemical circles as a more stable variant. The corpus of peer-reviewed Selank studies summarized on this site was conducted on Selank itself (Thr-Lys-Pro-Arg-Pro-Gly-Pro, TP-7) [1], so the mechanistic and clinical findings here describe the parent peptide. Claims that an acetylated variant has greater potency or duration in humans are not established in the literature reviewed here — a reminder that variant marketing often outruns the actual evidence. ## The honest gap in the Selank record The candid limit is the geography of the evidence. The overwhelming majority of Selank studies come from a small set of Russian groups — chiefly the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology — and many key papers are Russian-language with English abstracts only, which limits full methodological scrutiny [6]. Independent Western replication is limited, the pharmacokinetics of intact Selank in humans are poorly characterized, and most efficacy data are preclinical or from small clinical studies [6][16]. The findings are interesting and internally consistent; they are not a globally validated, FDA-cleared body of evidence, and this digest attributes them accordingly. --- A friendly, honestly-cited digest of the Selank research — bright on the page, careful with the evidence.